IL2 and cancer: Immune checkpoint inhibitors have now received FDA approval for first- and second-line treatment for various cancers (21), and favorable effectiveness has been seen in patients with metastasis and recurrence (22), such as the cytokines interferon-alpha (20), the interleukin-2 (IL-2) (23).